Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Comment by threefiftynineon May 30, 2020 10:55am

43 Views

Post# 31091678

RE:RE:------TIME TO GET OFF THE POTTY

--Lots of scenarios out there but so far apart from being on the WHO list (which ow means zilch) this company have underperformed thus far. We will find out within weeks whether this company bandwagoned covid or are a serious contender for the vaccine. PHASE1 is the catalyst ---without that this company will go back to the drawing board and will celebrate going from a nothing bio company to trading millions of shares daily and a high of .335 cents---keep your eyes on SEDI ---if they have something insiders will throw silly money along with institutional houses for their big payday down the road.

Bullboard Posts

Gold, growth and sustainability in focus for Mandalay Resources